2A arsland D, Tandberg E, Larsen JP, et al.Freguency of dementia in Parkinson's disease.Arch Neurol, 1996; 53 : 538.
3M artila RJ.Diagnos is an d epidemiology of Parkin- son's disease.Acta Neurol S can, 1983 ; 9 : 9.
4Leentjens AF, Vreeling FW, Luijckx GJ, et al.SSRIs in the treatment of depression in Parkinson's disease [J]. Int Geriatric Psychiatry, 2003 ; 18(6) :552-554.
5Dell'Agnello G,Ceravolo R,Nuti A,et al.SSRIs do not worsen Parkinson's disease:evidence from an open label prospective study [J]. Clin Neuropharma- col, 2001 ; 24 ( 4 ) : 221-227.
6van de Vijver DA, Roos RA,Jansen PA, et.al.Start of a selective serotonin reuptake inhibitor (SSRI) and increase of anti-Parkinsonian drug treatment in pa- tients on levodopa [J]. Br J Clin Pharmacol, 2002 ; 54 (2) : 168-170.
8Cummings JL.Depression and Parkinsons' disease:a review [J]. Am J Psychiatry, 1992; 194(4 ) :443.
9Giladi N,Treves TA,Psleacu D,et.al.Risk factors for dementia,depression and psychosis in long standing Parkinson's disease [J]. J Neural Tm ram, 2000;307( 1 ):59.
10Aarsland D,Lmsen JP,Lim NG,et.al.Rang e of nerrmpsychiatric disturbances in patients with Parkinson s' disease [J]. J N euro 1 Neurosurg Psy- chiatry, 1999; 67 (4) : 492.
二级参考文献21
1Polymeropoulos MH,Lavedan C,Leroy E,et al.Mutation in the α-synuclein gene identified in families with Parkinson's disease.Science,1997,276:2045-2047.
2Kruger R,Kuhn W,Muller T,et al.Ala30-to-pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.Nature Genet,1998,18:106-108.
3Souza JM,Giasson BI,Chen Q,et al.Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers.Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies.J Biol Chem,2000,275:18344-18349.
4Paik SR,Shin HJ,Lee JH.Metal-catalyzed oxidation of alphasynuclein in the presence of Copper (Ⅱ) and hydrogen peroxide.Arch Biochem Biophys,2000,378:269-277.
5Kim TD,Paik SR,Yang CH,et al.Structural changes in alphasynuclein affect its chaperone-like activity in vitro.Protein Science,2000,9:2489-2496.
6Perez RG,Waymire JC,Liu JJ,et al.A role for α-Synuclein in the Regulation of dopamine biosynthesis.J Neurosci,2002,22:3090-3099.
7Wacker JL,Zareie MH,Fong H,et al.Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer.Nat Struct Mol Biol,2004,11:1215-1222.
8Payton JE,Perrin RJ,Woods WS,et al.Structural determinants of PLD2 inhibition by alpha-synuclein.J Mol Biol,2004,337:1001-1009.
9Lehmensiek V,Tan EM,Schwarz J,et al.Expression of mutant alpha-synucleins enhances dopamine transporter-mediated MPP+toxicity in vitro.Neuroreport,2002,13:1279-1283.
10Ding TT,Lee SJ,Rochet JC,et al.Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes.Biochemistry,2002,41:10209-10217.
